Safety and Efficacy of Firmagon® (Degarelix) for Injection
The purpose of this study is to assess the safety and efficacy of Firmagon® (degarelix) for injection under the conditions of general clinical practice in Korea.
Prostate Cancer
DRUG: degarelix
Incidence of adverse events, Up to 12 months
The purpose of this study is to assess the safety and efficacy of Firmagon® (degarelix) for injection under the conditions of general clinical practice in Korea.